Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
Resverlogix's Phase 2 trials had pre-specified primary outcomes of apoAI, HDL-C or plaque reduction. The ALP and eGFR were never pre-specified primary or secondary outcomes; only post-hoc analyses. So even though they were statistically significant, post-hoc analyses are basically just hypothesis generating and require clinical follow up as a prespecified outcome in a follow up trial.
